From St. Mark's Hospital and St. Mark's Diabetes Center, Salt Lake City, Utah; Johns Hopkins University, Baltimore, Maryland; SinfoníaRx, Tucson, Arizona; Glytec, Marco Island, Florida; Touro University College of Osteopathic Medicine, Vallejo, California; Abington Memorial Hospital, Jenkintown, Pennsylvania; and University of Michigan, Ann Arbor, Michigan.
Ann Intern Med. 2017 Oct 3;167(7):493-498. doi: 10.7326/M17-1259. Epub 2017 Sep 12.
The American Diabetes Association (ADA) annually updates Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.
For the 2017 Standards of Care, the ADA Professional Practice Committee did MEDLINE searches from 1 January 2016 to November 2016 to add, clarify, or revise recommendations on the basis of new evidence. The committee rated the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards of Care were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions.
This synopsis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic approaches to glycemic management for type 1 diabetes.
美国糖尿病协会（ADA）每年更新《糖尿病医疗护理标准》，为临床医生、患者、研究人员、支付方和其他相关方提供基于证据的建议，以用于糖尿病患者的诊断和管理。
对于 2017 年的《医疗护理标准》，ADA 专业实践委员会进行了 MEDLINE 检索，检索日期为 2016 年 1 月 1 日至 2016 年 11 月，根据新证据添加、澄清或修改建议。委员会根据证据质量将建议评为 A、B 或 C，或根据专家共识或临床经验评为 E。《医疗护理标准》由 ADA 董事会执行委员会审查和批准，该委员会成员包括医疗保健专业人员、科学家和非专业人员。更广泛的临床社区的反馈意见促成了修订。
本概要重点介绍了 2017 年《医疗护理标准》中关于 1 型糖尿病血糖管理监测和药物治疗方法的推荐意见。
